The target BP level of less than 130/80 mm Hg for CKD patients—which is recommended by a Kidney Disease Outcomes Quality Initiative guideline—is not definitively supported by scientific data and could potentially lead to adverse effects.
A study of testosterone supplementation in older men was terminated after daily application of a testosterone gel was associated with a significantly increased risk of cardiovascular (CV) adverse events.
Low socioeconomic status (SES) increases blacks’ risk of developing CKD nearly twofold, but does not increase the risk in whites, according to a recent report in the American Journal of Kidney Diseases (2010;55:977-980).
A high resting heart rate and low beat-to-beat heart rate variability raises the odds of developing kidney disease, according to a study that examined data from 13,241 participants in the Atherosclerosis Risk in Communities study.
CHICAGO—Tasquinimod, a novel biologic agent, may significantly slow the rate of disease progression and improve progression-free survival in patients with metastatic castrate-resistant prostate cancer (CRCP), according to a new study presented at the American Society of Clinical Oncology annual meeting.